|1.||Candelario-Jalil, Eduardo: 1 article (02/2008)|
|2.||Taheri, Saeid: 1 article (02/2008)|
|3.||Estrada, Eduardo Y: 1 article (02/2008)|
|4.||Rosenberg, Gary A: 1 article (02/2008)|
|5.||Sood, Rohit R: 1 article (02/2008)|
|6.||Miller, K M: 1 article (01/2004)|
|7.||Hughes, R A C: 1 article (01/2004)|
|8.||Demestre, M: 1 article (01/2004)|
|9.||Wells, G M: 1 article (01/2004)|
|10.||Gearing, A J: 1 article (01/2004)|
01/01/2004 - "Thus despite the inhibition of MMPs by BB-1101, the drug did not appear to essentially affect nerve degeneration or regeneration following nerve crush but that it could be beneficial in promoting the more effective reinnervation of muscles possibly by actions at the level of the muscles."
03/01/1998 - "The aim of the present study was to determine the anti-inflammatory effects of the synthetic MMP inhibitor BB-1101 in acute anti-Thy1.1 nephritis. "
04/01/2001 - "First, we investigated the effect of the MMP inhibitor BB-1101 in anti-Thy1.1 nephritis. "
03/01/1998 - "These beneficial effects were less pronounced, but in part still significant, in animals treated by BB-1101 after induction of anti-Thy1.1 nephritis. "
|5.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
11/01/2002 - "Finally, IPC produced a reduction in infarct volume, which was inhibited by treatment with BB-1101 and with anti-TNF-alpha (10 microg/5 doses; SHAM + permanent middle cerebral artery occlusion [pMCAO], 335 +/- 20; IPC + pMCAO, 244 +/- 14; IPC + BB + pMCAO, 300 +/- 6; IPC + anti-TNF + pMCAO, 348 +/- 22 mm3; n = 6-10, < 0.05). "
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Hydroxamic Acids (Hydroxamic Acid)
|5.||Anti-Bacterial Agents (Antibiotics)
|6.||salicylhydroxamic acid (SHAM)